

Fenestra Research Labs

The World Leader In Wellness Studies

Case Study on

NaturLOCK™

Final Report
Winter 2014- 2015

Case Study #1

This was a 30-day four subject Case Study to evaluate the effects of NaturLOCK™ on symptoms of Crohn's disease.

Crohn's disease is a chronic inflammatory disease of the digestive tract characterized by severe chronic inflammation of the intestinal wall and or any portion of the gastrointestinal tract. The lower portion of the small intestine (ileum) and the rectum are most commonly affected by this disorder. The exact cause of Crohn's disease is unknown. Symptoms include abdominal pain and discomfort, diarrhea, and weight loss.

It is estimated that 700,000 Americans have this disease by the *Crohn's and Colitis Foundation of America*.

The inclusion for this study:


1. Prior diagnosis of Crohn's disease with at least 2 of the standard active symptoms persisting at least 3 times each month for a period of 3 months.
2. Between the ages of 50-65 years of age on the first day of testing.
3. No other complications that might prevent them from participating and completing this case study.

Two subjects were male and two were female. Each subject was provided NaturLOCK™ for the duration of this 30-day study period. Subjects were instructed to consume 4 ounces two times daily on an empty stomach, meaning they should have nothing else to eat or drink one hour prior and one hour after consuming the test product. Subjects were instructed to contact *Fenestra Research Staff* if they had any questions or concerns. Subjects were monitored on bi-weekly basis.

Baseline Testing

This Case Study remains the property of Terry Laboratories and Fenestra Research Labs. No copies in whole or part shall be used for any purpose without the approval of both parties.

www.fenestrasearch.com



Fenestra Research Labs

The World Leader In Wellness Studies

A sigmoidoscopy was performed by a licensed health care professional. For this examination a lighted tube was inserted through the anus. The flexible sigmoidoscopy was about 2.3 ft. (70 cm) long and 0.5 in. (1 cm) wide with a lighted lens system.

All four subjects presented with colonic lymphoid hyperplasia. Wall thickness and contrast enhancement of the bowel wall was present in all four subjects and a slight amount of blood was present in two of the subjects. Two subjects presented with 3-6 polyps, one subject presented with 8 polyps, one subject presented with no polyps.

Day 30 Retesting

Three of the subjects showed at least a 50% decrease in wall thickness. The two subjects with 3-6 polyps did not have any polyps present; the subject with eight polyps had 1 polyp present. No subjects have any sign of blood.

Absorption

Each subject underwent a Pharmacokinetics, meaning moving or putting into motion test. This part of the case study is used in determining the fate of the substances administered to a living organism and then observe and measure how much of what has been administered is uptake into the blood stream.

Subjects' first blood draw was done at Baseline before any test product had ever been consumed and again every hour for ten hours. Each draw was done from a vein in either the left or right arm. Three separate vials of blood were drawn with the recorded number being the average of that three. Each blood sample was tested fresh and never frozen or stored. A substantial amount of NaturLOCK™ was measured in the blood stream of each subject starting on hour one through hour five.


Conclusion

All four subjects experienced significant positive changes in their colon health. No subject reported any interactions or allergic effects for the duration of this study.

The subjects in this Case Study said they had more energy and felt more relaxed in the evenings than they had before the first day of this study. They all expressed that taking NaturLOCK™ was a positive experience for them.

This Case Study remains the property of Terry Laboratories and Fenestra Research Labs. No copies in whole or part shall be used for any purpose without the approval of both parties.

www.fenestrasearch.com



Fenestra Research Labs

The World Leader In Wellness Studies

The recommended dose based on this Case Study would be 4-6 ounces 2 times daily on an empty stomach.